Skip to content
Homepage
Clinic directory

Clinics in Indianapolis, Indiana

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Indianapolis, IN

Psychedelic Therapy clinics in Indianapolis

Psychedelic-assisted therapy in Indianapolis sits mostly in the ketamine-assisted psychotherapy category, with some clinics also preparing for state-specific psilocybin frameworks. Psychiatric referrals for complex cases route through IU Health, Ascension St Vincent, and Community Health Network. Demand reflects a pharma-industry (Lilly) and insurance-driven patient base.

Ketamine-assisted psychotherapy has the strongest US evidence base among psychedelic modalities. Psilocybin is not FDA approved and is only legally accessible within research or specific state programs. MDMA therapy is investigational. Clinics in Indianapolis, Indiana should be evaluated for therapist training, safety protocols, and honest evidence framing. Indiana Medical Licensing Board rules on delegation and physician supervision determines what can legally be offered.

With psychedelic therapy clinics on Regenerated.com in Indianapolis, patients can compare clinician training, integration support, and legal framework before booking.

1 Clinics

Indy Behavioral Health

Indianapolis, IN

Indy Behavioral Health, an integrative clinic in Indianapolis, offers ketamine therapy and esketamine (Spravato) alongside transcranial magnetic stimulation for treatment-resistant depression, anxiet…

  • Ozone Therapy
  • IV Therapy
  • Transcranial Magnetic Stimulation (TMS)
  • Hyperbaric Oxygen Therapy (HBOT)
  • Ketamine Therapy
15 30 50 results per page

Regulatory context

A note on Indiana's psychedelic therapy rules.

Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.

  • SB 139 / Psilocybin Research (2024)
    Authorized clinical research on psilocybin for treatment-resistant mental health conditions at Indiana universities; no therapeutic access framework.
  • Indiana Controlled Substances Act
    Mirrors federal scheduling.

Indiana enforces federal scheduling. The Indiana Medical Licensing Board oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Indiana INSPECT PDMP requires controlled substance reporting.

Sources: dea.gov · in.gov · in.gov · iga.in.gov

Psychedelic Therapy in Indianapolis, answered.

In Indiana, ketamine-assisted psychotherapy is the primary legal option. Ketamine is a Schedule III controlled substance prescribed off label for depression, anxiety, and PTSD. Psilocybin and MDMA are Schedule I federally and not legally available in Indiana. Only Oregon (Measure 109) and Colorado (Proposition 122) currently operate regulated psilocybin programs.

In Indianapolis, ketamine-assisted psychotherapy typically runs 400 to 900 dollars per session, with full protocols of six sessions costing 2,500 to 6,000 dollars. IM injection sessions tend to be less expensive than IV infusions. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and may be covered by insurance with prior authorization, though out-of-pocket copays vary. Integration therapy sessions are often billed separately at 150 to 300 dollars each.

Not as an FDA-approved treatment. In August 2024 the FDA issued a Complete Response Letter to Lykos Therapeutics (formerly MAPS PBC) for MDMA-assisted therapy for PTSD, citing concerns about trial design and data quality. MDMA remains Schedule I federally. Some expanded access and clinical trial pathways exist, but no Indianapolis clinic can legally prescribe MDMA outside of those frameworks. Lykos has stated it plans to resubmit following additional trial work.

Ketamine-assisted psychotherapy is used off-label for treatment-resistant depression, PTSD, anxiety, and suicidal ideation. Spravato (esketamine) carries FDA approval specifically for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior. Evidence quality is strongest for depression, with multiple randomized trials supporting short-term benefit. Indianapolis clinics typically screen for cardiovascular conditions, psychotic disorders, and active substance use before starting treatment.

Verify the prescriber on the Indiana medical board license lookup and NPI registry. Confirm the clinician has training in psychedelic-assisted therapy through MAPS, Fluence, Polaris, or a comparable program. Ask about screening protocols, emergency procedures, and whether a therapist is present during sessions. Check the FDA warning letter database. Avoid clinics promising guaranteed outcomes, pushing large prepaid packages, or operating outside of state licensure. Integration support should be part of any reputable protocol.

Explore related care

Related Treatments

Treatment guide

Learn about Psychedelic Therapy

What it is, how it works, and what to expect.

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology